Posted July 18, 2019
Reckitt Benckiser (RB Group) agreed to pay $1.4 billion to resolve US investigations over claims that its former pharmaceuticals business, Indivior carried out an illegal scheme to boost sales of an opioid addiction treatment. Indivior was accused of deceiving doctors into believing its product, Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar opioid drugs, and the company allegedly directed opioid-addicted patients to doctors who prescribed Suboxone at high rates. Indivior has pleaded not guilty to conspiracy and fraud charges and will face trial in federal court. Read more.